TY - JOUR
T1 - EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update
T2 - Treatment of Relapsing and Metastatic Prostate Cancer[Formula presented]
AU - Cornford, Philip
AU - van den Bergh, Roderick C N
AU - Briers, Erik
AU - den Broeck, Thomas Van
AU - Cumberbatch, Marcus G
AU - De Santis, Maria
AU - Fanti, Stefano
AU - Fossati, Nicola
AU - Gandaglia, Giorgio
AU - Gillessen, Silke
AU - Grivas, Nikolaos
AU - Grummet, Jeremy
AU - Henry, Ann M
AU - der Kwast, Theodorus H van
AU - Lam, Thomas B
AU - Lardas, Michael
AU - Liew, Matthew
AU - Mason, Malcolm D
AU - Moris, Lisa
AU - Oprea-Lager, Daniela E
AU - der Poel, Henk G van
AU - Rouvière, Olivier
AU - Schoots, Ivo G
AU - Tilki, Derya
AU - Wiegel, Thomas
AU - Willemse, Peter-Paul M
AU - Mottet, Nicolas
N1 - Funding Information:
Financial disclosures: Philip Cornford certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Philip Cornford is a company consultant for Astellas, Ipsen, and Ferring; received company speaker honoraria from Astellas, Janssen, Ipsen, and Pfizer; participated in trials run by Ferring; and received fellowships and travel grants from Astellas and Janssen. Dr. E. Briers has received grant and research support from Ipsen, the EAU, and Bayer; is an ex-officio board member for Europa UOMO; is an ethics committee and advisory group member for REQUITE; is a patient advisory board member for PAGMI; and is a member of SCA and EMA PCWP. Professor Dr. M. De Santis is a company consultant for Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai Inc, ESSA, Ferring, GSK, Incyte, Ipsen, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, Teva, OncoGenex, and Sandoz; receives speaker honoraria from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ferring, GSK, Ipsen, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, Synthon, and Takeda; participates in trials run by the Technical University Munich, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai Inc, Ferring, GSK, Ipsen, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SOTIO, and Cancer Research UK; participates in various trials as a member of the EORTC GU group; has received research grants from Pierre Fabre Oncologie; and has received travel grants from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Ferring, GSK, Ipsen, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, and Teva/OncoGenex. Professor Dr. S. Fanti is a company consultant for Bayer and ANMI; has received speaker honorarium from Bayer, Genzyme, ANMI, and GE Healthcare; and participates in trials by Amgen, Bayer, BMS, Genzyme, Janssen, Merck, and Novartis. Professor Dr. S. Gillessen is a company consultant for AAA International, Astellas Pharma, Bayer, Bristol-Myers Squibb, Clovis, CureVac, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxIVAX SA, Orion, Roche, Sanofi Aventis Group, Nectar, and ProteoMediX; received speaker honorarium from Janssen and Novartis; and participates in multiple trials from different companies. Professor Dr. J.P. Grummet received speaker honorarium from Mundipharma, a travel grant from Astellas and a research grant from Cancer Australia; and is the owner of MRI PRO Pty Ltd., an online training platform. Professor Dr. A.M. Henry is a company consultant for Nucletron-Elektra; participates in trials by Cancer Research UK and the National Institute of Health Research (UK); received travel grants from the Medical Research Council, the National Institute of Health Research (UK), and Cancer Research UK; and received research grants from Cancer Research UK and the Sir John Fisher Foundation. Dr. T.B.L. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GSK, Astellas, and Ipsen. Professor Dr. M.D. Mason is a company consultant for Ellipses Pharma and Oncotherics. Professor Dr. D. Tilki received speaker honorarium from Astellas and a travel grant from Janssen. Professor Dr. H.G. van der Poel is a company consultant for Intuitive Surgical; has participated in trials for Astellas and Steba Biotech; and has received grant and research support from Astellas. Professor Dr. T. Wiegel is an advisory board member for Ipsen; receives company speaker honoraria from Ipsen and Hexal; is a member of the Janssen Steering Committee; and has participated in the ATLAS/AUO trial. Professor Dr. N. Mottet is a company consultant for Janssen, GE, BMS, Sanofi, Ipsen, AstraZeneca, Carrik, Arquer Diagnostics, Takeda, Bayer, and Astellas; has received speaker honoraria from Astellas, Pierre Fabre, Steba, Janssen, and Ferring; and has received fellowships and travel grants from Astellas, Ipsen, Sanofi, Janssen, and Roche. Dr. R.C.N. van den Bergh, Professor Dr. O. Rouvière, Professor Dr. T.H. van Der Kwast, Dr. T. Van den Broeck, Mr. M.G. Cumberbatch, Dr. N. Fossati, Dr. G. Gandaglia, Dr. N. Grivas, Dr. M. Lardas, Mr. M. Liew, Dr. L. Moris, Dr. D.E. Oprea-Lager, Dr. I.G. Schoots, and Dr. P-P. M. Willemse have nothing to declare.
Publisher Copyright:
© 2020
PY - 2021/2
Y1 - 2021/2
N2 - Objective: To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy & Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC). Evidence acquisition: The working panel performed a literature review of the new data (2016–2019). The guidelines were updated, and the levels of evidence and/or grades of recommendation were added based on a systematic review of the literature. Evidence synthesis: Prostate-specific membrane antigen positron emission tomography computed tomography scanning has developed an increasingly important role in men with biochemical recurrence after local therapy. Early salvage radiotherapy after radical prostatectomy appears as effective as adjuvant radiotherapy and, in a subset of patients, should be combined with androgen deprivation. New treatments have become available for men with metastatic hormone-sensitive prostate cancer (PCa), nonmetastatic CRPC, and metastatic CRPC, along with a role for local radiotherapy in men with low-volume metastatic hormone-sensitive PCa. Also included is information on quality of life outcomes in men with PCa. Conclusions: The knowledge in the field of advanced and metastatic PCa and CRPC is changing rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for use in clinical practice. These PCa guidelines are first endorsed by the EANM and reflect the multidisciplinary nature of PCa management. A full version is available from the EAU office or online (http://uroweb.org/guideline/prostate-cancer/). Patient summary: This article summarises the guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are evidence based and guide the clinician in the discussion with the patient on the treatment decisions to be taken. These guidelines are updated every year; this summary spans the 2017–2020 period of new evidence. The knowledge in the field of advanced and metastatic prostate cancer (PCa) and castration-resistant prostate cancer is changing rapidly. The 2020 European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy & Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on PCa summarise the most recent findings and advice for use in clinical practice. These PCa guidelines are first endorsed by the EANM and reflect the multidisciplinary nature of PCa management. A full version is available from the EAU office or online (http://uroweb.org/guideline/prostate-cancer/).
AB - Objective: To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy & Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC). Evidence acquisition: The working panel performed a literature review of the new data (2016–2019). The guidelines were updated, and the levels of evidence and/or grades of recommendation were added based on a systematic review of the literature. Evidence synthesis: Prostate-specific membrane antigen positron emission tomography computed tomography scanning has developed an increasingly important role in men with biochemical recurrence after local therapy. Early salvage radiotherapy after radical prostatectomy appears as effective as adjuvant radiotherapy and, in a subset of patients, should be combined with androgen deprivation. New treatments have become available for men with metastatic hormone-sensitive prostate cancer (PCa), nonmetastatic CRPC, and metastatic CRPC, along with a role for local radiotherapy in men with low-volume metastatic hormone-sensitive PCa. Also included is information on quality of life outcomes in men with PCa. Conclusions: The knowledge in the field of advanced and metastatic PCa and CRPC is changing rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for use in clinical practice. These PCa guidelines are first endorsed by the EANM and reflect the multidisciplinary nature of PCa management. A full version is available from the EAU office or online (http://uroweb.org/guideline/prostate-cancer/). Patient summary: This article summarises the guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are evidence based and guide the clinician in the discussion with the patient on the treatment decisions to be taken. These guidelines are updated every year; this summary spans the 2017–2020 period of new evidence. The knowledge in the field of advanced and metastatic prostate cancer (PCa) and castration-resistant prostate cancer is changing rapidly. The 2020 European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy & Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on PCa summarise the most recent findings and advice for use in clinical practice. These PCa guidelines are first endorsed by the EANM and reflect the multidisciplinary nature of PCa management. A full version is available from the EAU office or online (http://uroweb.org/guideline/prostate-cancer/).
KW - Castration resistant
KW - Chemotherapy
KW - EAU-EANM-ESTRO-ESUR-SIOG guidelines
KW - Follow-up
KW - Hormonal therapy
KW - Metastatic
KW - Palliative
KW - Prostate cancer
KW - Quality of life
KW - Relapse
UR - http://www.scopus.com/inward/record.url?scp=85092248792&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2020.09.046
DO - 10.1016/j.eururo.2020.09.046
M3 - Review article
C2 - 33039206
SN - 0302-2838
VL - 79
SP - 263
EP - 282
JO - European Urology
JF - European Urology
IS - 2
ER -